Imaging method for ocular diseases uses new approach
August 15th 2011Quantitative in vivo assessment of retinal blood flow attained with ultra-high-speed swept source/Fourier-domain optical coherence tomography could be beneficial for assessing pathologic changes in ocular diseases associated with abnormalities in retinal blood flow.
Ford 'Super Vision Center' opens
August 10th 2011The Henry Ford OptimEyes Super Vision Center has opened in the new Henry Ford Medical Center. The 140,000-square-foot facility includes 65,000 square feet of space for the Henry Ford OptimEyes Super Vision Center, with the remaining space expected to be leased out to private-practice physicians.
Results: Bromfenac same as placebo
August 10th 2011Initial top-line results from a Phase III study of bromfenac ophthalmic solution (Remura, ISTA Pharmaceuticals) indicate that bromfenac was not statistically superior to placebo in treating one sign and one symptom of dry eye disease. ISTA announced this result from the WEST study, the first of two phase III safety and efficacy studies being conducted under a special protocol assessment (SPA) agreed upon with the FDA.
Dexamethasone insert recommended
August 3rd 2011The National Institute for Health and Clinical Excellence (NICE), an independent advisory organization in England, has recommended use of a 0.7-mg dexamethasone intravitreal implant in an applicator (Ozudex, Allergan) for the treatment of macular edema due to central retinal vein occlusion (CRVO) as well as for branch retinal vein occlusion (BRVO) in cases in which laser photocoagulation is neither beneficial nor appropriate.
Genomics help decode eye disease
August 1st 2011Breakthroughs in genetics and genomics will change our view of biology in coming decades, helping identify the causes of all single-gene eye diseases, gain insight into disease gene functions, untangle the genetics of common eye diseases, and bring the promise-and potential downsides-of personalized medicine into the clinic.